Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer Inc. (NYSE: PFE) has launched PfizerForAll, a digital platform aimed at simplifying healthcare access for millions of Americans. The platform focuses on patients with migraine, COVID-19, or flu, and adults seeking vaccines for preventable diseases. PfizerForAll offers:
- Same-day appointments with healthcare professionals
- Home delivery of medicines and diagnostic tests
- Vaccine appointment scheduling
- Help with paying for Pfizer medicines
- Access to patient support services
The platform works within the existing healthcare system and partners with organizations like UpScriptHealth, Alto Pharmacy, and Instacart. This initiative responds to the overwhelming nature of the U.S. healthcare system, with 65% of Americans finding healthcare coordination overwhelming and time-consuming.
Pfizer (NYSE: PFE) announced positive top-line results from substudy B of the Phase 3 MONeT trial, evaluating ABRYSVO vaccine in immunocompromised adults at risk of severe RSV-associated lower respiratory tract disease. The study involved 203 adults across four groups: non-small cell lung cancer patients, hemodialysis patients, autoimmune disorder patients on immunomodulator therapy, and solid organ transplant recipients.
Key findings:
- ABRYSVO was well-tolerated with a safety profile consistent with previous studies
- A single 120 µg dose generated strong neutralizing responses against RSV-A and RSV-B across all cohorts and age groups
- Results support ABRYSVO's potential to address unmet needs in vulnerable populations aged 18-59
Pfizer plans to share these findings at an upcoming scientific conference and submit data to regulatory agencies for review.
Pfizer (NYSE: PFE) reported robust second-quarter 2024 financial results, driving a raise in full-year 2024 revenue guidance to $59.5-$62.5 billion and adjusted diluted EPS to $2.45-$2.65. The company's revenue hit $13.3 billion, growing 3% operationally year-over-year, despite a decline in COVID-related revenues. Excluding Comirnaty and Paxlovid, revenues surged by 14%. Reported diluted EPS was $0.01, impacted by $1.3 billion in one-time manufacturing optimization costs, while adjusted diluted EPS was $0.60. Pfizer anticipates $1.5 billion in cost savings from its Manufacturing Optimization Program by 2027.
Key product highlights include a 71% operational growth for the Vyndaqel family, 8% for Eliquis, and 44% for Nurtec ODT/Vydura. However, Xeljanz and Ibrance saw declines of 34% and 8% operationally, respectively. Pfizer also announced advancements in its R&D pipeline and several product developments.
Pfizer's DURVEQTIX® (fidanacogene elaparvovec), a one-time gene therapy for adults with severe and moderately severe hemophilia B, has received conditional marketing authorization from the European Commission. This innovative treatment is designed to enable patients to produce factor IX themselves, potentially eliminating the need for frequent intravenous infusions. Key highlights:
- Demonstrated a median annualized bleed rate of zero bleeds after up to four years of follow-up
- Approved for adult patients without a history of factor IX inhibitors and without detectable antibodies to variant AAV serotype Rh74
- Met primary efficacy endpoint in Phase 3 BENEGENE-2 study
- Generally well-tolerated with a safety profile consistent with Phase 1/2 results
- Builds on Pfizer's 40-year commitment to hemophilia treatment innovation
Pfizer (NYSE: PFE) announced positive topline results from the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, a gene therapy for hemophilia A. The study met its primary objective of non-inferiority and superiority in total annualized bleeding rate (ABR) compared to routine Factor VIII replacement prophylaxis. Key findings include:
- Significant reduction in mean total ABR (1.24 vs 4.73)
- 84% of participants maintained FVIII activity >5% at 15 months post-infusion
- 98.3% reduction in mean treated ABR (4.08 to 0.07)
- Generally well-tolerated safety profile
Pfizer plans to discuss these data with regulatory authorities and advance the therapy to address the treatment burden for hemophilia A patients.
ViiV Healthcare announced positive 48-week results from the PASO DOBLE study, comparing the 2-drug regimen Dovato (dolutegravir/lamivudine) to the 3-drug regimen Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide fumarate) for HIV-1 treatment. The study showed that:
1. Dovato demonstrated non-inferior efficacy in maintaining viral suppression compared to Biktarvy.
2. Participants taking Dovato experienced significantly less weight gain compared to those on Biktarvy.
3. Safety profiles were comparable between both regimens.
These findings support Dovato as an effective treatment option for virologically-suppressed adults living with HIV, addressing concerns about treatment-related weight gain.
CytoReason, a leader in computational disease modeling, has secured $80 million in funding from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific. The investment will be used to expand disease models, grow proprietary data, and establish a US hub in Cambridge, Massachusetts. CytoReason's technology provides molecular-level insights and AI tools to help pharma companies make data-driven R&D decisions, improving the probability of phase 2 success.
The company has partnerships with six of the world's top ten pharma companies and has published numerous scientific articles in prestigious journals. This funding round highlights the growing importance of AI and data modeling in pharmaceutical R&D, with investors recognizing CytoReason's potential to revolutionize drug development processes.
ViiV Healthcare, majority owned by GSK, will present 25 abstracts at the 25th International AIDS Conference in Munich, including the largest head-to-head randomized clinical trial comparing their 2-drug regimen Dovato against the 3-drug regimen Biktarvy. Key presentations include:
1. PASO-DOBLE study: 48-week findings on treatment efficacy, safety, and weight changes for Dovato vs Biktarvy
2. Pregnancy data for Apretude (cabotegravir long-acting injectable) for PrEP
3. Phase I findings of VH184, a third-generation integrase inhibitor with potential for ultra long-acting applications
4. Real-world evidence for long-acting treatment regimen Cabenuva
These presentations underscore ViiV Healthcare's leadership in developing long-acting and 2-drug regimens for HIV treatment and prevention, addressing patient needs beyond viral suppression.
Pfizer announced progress in developing a once-daily formulation of the oral GLP-1 receptor agonist danuglipron, showing promising pharmacokinetic data for several candidates. Based on the ongoing pharmacokinetic study NCT06153758, Pfizer selected its preferred formulation and will conduct dose optimization studies in the second half of 2024. Danuglipron, which has shown good efficacy in its twice-daily form, is pivotal in Pfizer's obesity treatment pipeline. The ongoing study has confirmed a supportive pharmacokinetic profile for once-daily dosing and a consistent safety profile with no liver enzyme elevations in over 1,400 participants. The company aims to advance danuglipron into registration-enabling studies to address the medical needs of people living with obesity.
Pfizer (NYSE: PFE) has announced the commencement of a search for a successor to Dr. Mikael Dolsten, their Chief Scientific Officer and President of Research & Development. Dr. Dolsten, who has been with Pfizer for over 15 years, will assist in the transition and stay on until a successor is appointed. During his tenure, over 35 drugs and vaccines were approved, including significant accomplishments like the COVID-19 vaccine. The search process is expected to take several months, extending into early next year. Pfizer’s CEO, Albert Bourla, praised Dr. Dolsten for his contributions to the company and the scientific community.